0

Close
 
Upcoming Allied Market Research
2023
Neoantigen Market

Neoantigen Market

by Type (Nucleic Acid, Dendritic Acid, Tumor Cell, Synthetic Long Peptide), by Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, Others), by Product (Personalized Neo-Antigen Vaccine, Off-The Shell Neo-Antigen Vaccine), by Cell (Autologous, Allogeneic), by Treatment (Combination Therapy, Mono Therapy), by Technology (Whole Genome Sequencing, RNA Sequencing, HLA Typing), by Route of Administration (Intravenous, Intramuscular, Transdermal, Others) and by Delivery Mechanism (Gene Gun, Electroporation, Liposomes, Virosomes, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Diagnostics and Biotech
Report Code: A13363
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Neoantigen Market

Request Now !

Neoantigen is a protein that forms on the cancerous cells as a result on mutations in the tumorous DNA. They are thus used in development on vaccines and immunotherapies against cancer cells. Neoantigens are recognized in the body by neoantigen-specific T cell receptors (TCRs). Neoantigen-based vaccines and target therapies have shown promising results in various clinical trials, owing to the fact that they can be recognized as non-self/foreign and germline by the host’s immune system. Neoantigens find huge significance in cancer immunoediting. It is a technique used to establish dual roles of immune system with respect to tumor growth. Several studies have postulated the fact that neoantigen immunotherapy can in fact aid in controlling tumor outgrowth, facilitate cellular transformation and share immunogenicity of tumors. Furthermore, neoantigens can be divided into personalized neoantigens and shared neoantigens. Shared neoantigens are not present specifically in regards to individualized genome while personalized neontigens are targeted on specific individuals. Prediction on the number of neoantigens present involves a well thought validated algorithms to select more reliable neoepitopes. The procedure for development of neoantigen cancer vaccine involves obtaining tumorous tissues from the patient and subsequently identifying mutant genes of the tumor. Post this, RNA/DNA sequent test is carried out to select appropriate mutated antigens. Finally, these mutated antigens are designed into suitable vaccines.

COVID-19 Impact Analysis

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global neoantigens market.

Top Impacting Factors

  • Rise in the case of cancer and other chronic diseases coupled with growing demand for advanced therapeutic medications for quick, reliable, and sustainable treatment of cancer is anticipated to drive neoantigens market growth.
  • Recent clinical advancements in biotechnology and growing investments being influx in study of neoantigens and related mechanisms is slated to further boost study of neoantigens market. The trend is more visible in regions with high skilled biotechnological human resource, more economic muscle and internet penetration.
  • Inception of private sector global and regional player who are willing to spend more for design and development of novel medications for eradication or chronic diseases through more clinical trials, frequent product launches, and necessary collaborations & mergers may further fuel the market growth of neoantigens.
  • However, higher cost associated with design and development of personalized cancer medicines may hamper market growth. The factor may largely be visible in regions which lack efficient healthcare infrastructure and fragile government support.
  • Further optimization obstacles and clinical development delays mainly owing to shift of healthcare mechanisms towards battling COVID-19 may further hamper global neoantigen market outlook.

Key Market Trends

  • North America is anticipated to show dominance in neoantigen market owing to rising cases of cancer in the region coupled with growing demand of development of advanced treatment mechanisms.
  • BioNTech S.E. recently developed and launched individualized vaccine against cancer (IVAC) platform that helps in production of customized neoantigen vaccines.
  • Further, Genocea Biosciences developed ATLAS platform for development of neoantigen vaccines. It makes use of an ex-vivo method to treat melanoma, carcinoma, and lung cancers.
  • Agenus Inc. developed AutoSynVax (ASV) neoantigen vaccine to treat solid tumors. It is administered in addition to the adjuvant QS-21 Stimulon.

Key Benefits of the Report

  • This study presents the analytical depiction of the neoantigens industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the neoantigens market share.
  • The current market is quantitatively analyzed to highlight the neoantigens growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Neoantigens Report

  • Which are the leading players active in the neoantigens market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the neoantigens market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is neoantigens?
  • What is the neoantigens market prediction in the future?
  • What are the current trends and predicted trends?

 Neoantigen Market Report Highlights

Aspects Details
By Type
  • Nucleic Acid
  • Dendritic Acid
  • Tumor Cell
  • Synthetic Long Peptide
By Therapeutic Specialty
  • Gastrointestinal Cancer
  • Lung Cancer
  • Solid Tumor
  • Urinary Systems Cancers
  • Melanoma
  • Head and Neck Cancer
  • Others
By Product
  • Personalized Neo-Antigen Vaccine
  • Off-The Shell Neo-Antigen Vaccine
By Cell
  • Autologous
  • Allogeneic
By Treatment
  • Combination Therapy
  • Mono Therapy
By Technology
  • Whole Genome Sequencing
  • RNA Sequencing
  • HLA Typing
By Route of Administration
  • Intravenous
  • Intramuscular
  • Transdermal
  • Others
By Delivery Mechanism
  • Gene Gun
  • Electroporation
  • Liposomes
  • Virosomes
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Moderna, Inc., Merck & Co. Inc, Gradalis, Inc., Genocea, Ziopharm Oncology, Inc., Achilles Therapeutics plc, Gritstone Oncology, Advaxis, Inc., Frame Cancer Therapeutics, Immunicum AB, Medigene AG
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: NEOANTIGEN MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Nucleic Acid

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Dendritic Acid

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Tumor Cell

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Synthetic Long Peptide

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: NEOANTIGEN MARKET, BY THERAPEUTIC SPECIALTY

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Therapeutic Specialty

    • 5.2. Gastrointestinal Cancer

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Lung Cancer

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Solid Tumor

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Urinary Systems Cancers

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Melanoma

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Head And Neck Cancer

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

    • 5.8. Others

      • 5.8.1. Key Market Trends, Growth Factors and Opportunities

      • 5.8.2. Market Size and Forecast, By Region

      • 5.8.3. Market Share Analysis, By Country

  • CHAPTER 6: NEOANTIGEN MARKET, BY PRODUCT

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Product

    • 6.2. Personalized Neo-Antigen Vaccine

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Off-The Shell Neo-Antigen Vaccine

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

  • CHAPTER 7: NEOANTIGEN MARKET, BY CELL

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Cell

    • 7.2. Autologous

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Allogeneic

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

  • CHAPTER 8: NEOANTIGEN MARKET, BY TREATMENT

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Treatment

    • 8.2. Combination Therapy

      • 8.2.1. Key Market Trends, Growth Factors and Opportunities

      • 8.2.2. Market Size and Forecast, By Region

      • 8.2.3. Market Share Analysis, By Country

    • 8.3. Mono Therapy

      • 8.3.1. Key Market Trends, Growth Factors and Opportunities

      • 8.3.2. Market Size and Forecast, By Region

      • 8.3.3. Market Share Analysis, By Country

  • CHAPTER 9: NEOANTIGEN MARKET, BY TECHNOLOGY

    • 9.1. Market Overview

      • 9.1.1 Market Size and Forecast, By Technology

    • 9.2. Whole Genome Sequencing

      • 9.2.1. Key Market Trends, Growth Factors and Opportunities

      • 9.2.2. Market Size and Forecast, By Region

      • 9.2.3. Market Share Analysis, By Country

    • 9.3. RNA Sequencing

      • 9.3.1. Key Market Trends, Growth Factors and Opportunities

      • 9.3.2. Market Size and Forecast, By Region

      • 9.3.3. Market Share Analysis, By Country

    • 9.4. HLA Typing

      • 9.4.1. Key Market Trends, Growth Factors and Opportunities

      • 9.4.2. Market Size and Forecast, By Region

      • 9.4.3. Market Share Analysis, By Country

  • CHAPTER 10: NEOANTIGEN MARKET, BY ROUTE OF ADMINISTRATION

    • 10.1. Market Overview

      • 10.1.1 Market Size and Forecast, By Route Of Administration

    • 10.2. Intravenous

      • 10.2.1. Key Market Trends, Growth Factors and Opportunities

      • 10.2.2. Market Size and Forecast, By Region

      • 10.2.3. Market Share Analysis, By Country

    • 10.3. Intramuscular

      • 10.3.1. Key Market Trends, Growth Factors and Opportunities

      • 10.3.2. Market Size and Forecast, By Region

      • 10.3.3. Market Share Analysis, By Country

    • 10.4. Transdermal

      • 10.4.1. Key Market Trends, Growth Factors and Opportunities

      • 10.4.2. Market Size and Forecast, By Region

      • 10.4.3. Market Share Analysis, By Country

    • 10.5. Others

      • 10.5.1. Key Market Trends, Growth Factors and Opportunities

      • 10.5.2. Market Size and Forecast, By Region

      • 10.5.3. Market Share Analysis, By Country

  • CHAPTER 11: NEOANTIGEN MARKET, BY DELIVERY MECHANISM

    • 11.1. Market Overview

      • 11.1.1 Market Size and Forecast, By Delivery Mechanism

    • 11.2. Gene Gun

      • 11.2.1. Key Market Trends, Growth Factors and Opportunities

      • 11.2.2. Market Size and Forecast, By Region

      • 11.2.3. Market Share Analysis, By Country

    • 11.3. Electroporation

      • 11.3.1. Key Market Trends, Growth Factors and Opportunities

      • 11.3.2. Market Size and Forecast, By Region

      • 11.3.3. Market Share Analysis, By Country

    • 11.4. Liposomes

      • 11.4.1. Key Market Trends, Growth Factors and Opportunities

      • 11.4.2. Market Size and Forecast, By Region

      • 11.4.3. Market Share Analysis, By Country

    • 11.5. Virosomes

      • 11.5.1. Key Market Trends, Growth Factors and Opportunities

      • 11.5.2. Market Size and Forecast, By Region

      • 11.5.3. Market Share Analysis, By Country

    • 11.6. Others

      • 11.6.1. Key Market Trends, Growth Factors and Opportunities

      • 11.6.2. Market Size and Forecast, By Region

      • 11.6.3. Market Share Analysis, By Country

  • CHAPTER 12: NEOANTIGEN MARKET, BY REGION

    • 12.1. Market Overview

      • 12.1.1 Market Size and Forecast, By Region

    • 12.2. North America

      • 12.2.1. Key Market Trends and Opportunities

      • 12.2.2. Market Size and Forecast, By Type

      • 12.2.3. Market Size and Forecast, By Therapeutic Specialty

      • 12.2.4. Market Size and Forecast, By Product

      • 12.2.5. Market Size and Forecast, By Cell

      • 12.2.6. Market Size and Forecast, By Treatment

      • 12.2.7. Market Size and Forecast, By Technology

      • 12.2.8. Market Size and Forecast, By Route Of Administration

      • 12.2.9. Market Size and Forecast, By Delivery Mechanism

      • 12.2.10. Market Size and Forecast, By Country

      • 12.2.11. U.S. Neoantigen Market

        • 12.2.11.1. Market Size and Forecast, By Type
        • 12.2.11.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.2.11.3. Market Size and Forecast, By Product
        • 12.2.11.4. Market Size and Forecast, By Cell
        • 12.2.11.5. Market Size and Forecast, By Treatment
        • 12.2.11.6. Market Size and Forecast, By Technology
        • 12.2.11.7. Market Size and Forecast, By Route Of Administration
        • 12.2.11.8. Market Size and Forecast, By Delivery Mechanism

      • 12.2.12. Canada Neoantigen Market

        • 12.2.12.1. Market Size and Forecast, By Type
        • 12.2.12.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.2.12.3. Market Size and Forecast, By Product
        • 12.2.12.4. Market Size and Forecast, By Cell
        • 12.2.12.5. Market Size and Forecast, By Treatment
        • 12.2.12.6. Market Size and Forecast, By Technology
        • 12.2.12.7. Market Size and Forecast, By Route Of Administration
        • 12.2.12.8. Market Size and Forecast, By Delivery Mechanism

      • 12.2.13. Mexico Neoantigen Market

        • 12.2.13.1. Market Size and Forecast, By Type
        • 12.2.13.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.2.13.3. Market Size and Forecast, By Product
        • 12.2.13.4. Market Size and Forecast, By Cell
        • 12.2.13.5. Market Size and Forecast, By Treatment
        • 12.2.13.6. Market Size and Forecast, By Technology
        • 12.2.13.7. Market Size and Forecast, By Route Of Administration
        • 12.2.13.8. Market Size and Forecast, By Delivery Mechanism

    • 12.3. Europe

      • 12.3.1. Key Market Trends and Opportunities

      • 12.3.2. Market Size and Forecast, By Type

      • 12.3.3. Market Size and Forecast, By Therapeutic Specialty

      • 12.3.4. Market Size and Forecast, By Product

      • 12.3.5. Market Size and Forecast, By Cell

      • 12.3.6. Market Size and Forecast, By Treatment

      • 12.3.7. Market Size and Forecast, By Technology

      • 12.3.8. Market Size and Forecast, By Route Of Administration

      • 12.3.9. Market Size and Forecast, By Delivery Mechanism

      • 12.3.10. Market Size and Forecast, By Country

      • 12.3.11. France Neoantigen Market

        • 12.3.11.1. Market Size and Forecast, By Type
        • 12.3.11.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.3.11.3. Market Size and Forecast, By Product
        • 12.3.11.4. Market Size and Forecast, By Cell
        • 12.3.11.5. Market Size and Forecast, By Treatment
        • 12.3.11.6. Market Size and Forecast, By Technology
        • 12.3.11.7. Market Size and Forecast, By Route Of Administration
        • 12.3.11.8. Market Size and Forecast, By Delivery Mechanism

      • 12.3.12. Germany Neoantigen Market

        • 12.3.12.1. Market Size and Forecast, By Type
        • 12.3.12.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.3.12.3. Market Size and Forecast, By Product
        • 12.3.12.4. Market Size and Forecast, By Cell
        • 12.3.12.5. Market Size and Forecast, By Treatment
        • 12.3.12.6. Market Size and Forecast, By Technology
        • 12.3.12.7. Market Size and Forecast, By Route Of Administration
        • 12.3.12.8. Market Size and Forecast, By Delivery Mechanism

      • 12.3.13. Italy Neoantigen Market

        • 12.3.13.1. Market Size and Forecast, By Type
        • 12.3.13.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.3.13.3. Market Size and Forecast, By Product
        • 12.3.13.4. Market Size and Forecast, By Cell
        • 12.3.13.5. Market Size and Forecast, By Treatment
        • 12.3.13.6. Market Size and Forecast, By Technology
        • 12.3.13.7. Market Size and Forecast, By Route Of Administration
        • 12.3.13.8. Market Size and Forecast, By Delivery Mechanism

      • 12.3.14. Spain Neoantigen Market

        • 12.3.14.1. Market Size and Forecast, By Type
        • 12.3.14.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.3.14.3. Market Size and Forecast, By Product
        • 12.3.14.4. Market Size and Forecast, By Cell
        • 12.3.14.5. Market Size and Forecast, By Treatment
        • 12.3.14.6. Market Size and Forecast, By Technology
        • 12.3.14.7. Market Size and Forecast, By Route Of Administration
        • 12.3.14.8. Market Size and Forecast, By Delivery Mechanism

      • 12.3.15. UK Neoantigen Market

        • 12.3.15.1. Market Size and Forecast, By Type
        • 12.3.15.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.3.15.3. Market Size and Forecast, By Product
        • 12.3.15.4. Market Size and Forecast, By Cell
        • 12.3.15.5. Market Size and Forecast, By Treatment
        • 12.3.15.6. Market Size and Forecast, By Technology
        • 12.3.15.7. Market Size and Forecast, By Route Of Administration
        • 12.3.15.8. Market Size and Forecast, By Delivery Mechanism

      • 12.3.16. Russia Neoantigen Market

        • 12.3.16.1. Market Size and Forecast, By Type
        • 12.3.16.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.3.16.3. Market Size and Forecast, By Product
        • 12.3.16.4. Market Size and Forecast, By Cell
        • 12.3.16.5. Market Size and Forecast, By Treatment
        • 12.3.16.6. Market Size and Forecast, By Technology
        • 12.3.16.7. Market Size and Forecast, By Route Of Administration
        • 12.3.16.8. Market Size and Forecast, By Delivery Mechanism

      • 12.3.17. Rest Of Europe Neoantigen Market

        • 12.3.17.1. Market Size and Forecast, By Type
        • 12.3.17.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.3.17.3. Market Size and Forecast, By Product
        • 12.3.17.4. Market Size and Forecast, By Cell
        • 12.3.17.5. Market Size and Forecast, By Treatment
        • 12.3.17.6. Market Size and Forecast, By Technology
        • 12.3.17.7. Market Size and Forecast, By Route Of Administration
        • 12.3.17.8. Market Size and Forecast, By Delivery Mechanism

    • 12.4. Asia-Pacific

      • 12.4.1. Key Market Trends and Opportunities

      • 12.4.2. Market Size and Forecast, By Type

      • 12.4.3. Market Size and Forecast, By Therapeutic Specialty

      • 12.4.4. Market Size and Forecast, By Product

      • 12.4.5. Market Size and Forecast, By Cell

      • 12.4.6. Market Size and Forecast, By Treatment

      • 12.4.7. Market Size and Forecast, By Technology

      • 12.4.8. Market Size and Forecast, By Route Of Administration

      • 12.4.9. Market Size and Forecast, By Delivery Mechanism

      • 12.4.10. Market Size and Forecast, By Country

      • 12.4.11. China Neoantigen Market

        • 12.4.11.1. Market Size and Forecast, By Type
        • 12.4.11.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.4.11.3. Market Size and Forecast, By Product
        • 12.4.11.4. Market Size and Forecast, By Cell
        • 12.4.11.5. Market Size and Forecast, By Treatment
        • 12.4.11.6. Market Size and Forecast, By Technology
        • 12.4.11.7. Market Size and Forecast, By Route Of Administration
        • 12.4.11.8. Market Size and Forecast, By Delivery Mechanism

      • 12.4.12. Japan Neoantigen Market

        • 12.4.12.1. Market Size and Forecast, By Type
        • 12.4.12.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.4.12.3. Market Size and Forecast, By Product
        • 12.4.12.4. Market Size and Forecast, By Cell
        • 12.4.12.5. Market Size and Forecast, By Treatment
        • 12.4.12.6. Market Size and Forecast, By Technology
        • 12.4.12.7. Market Size and Forecast, By Route Of Administration
        • 12.4.12.8. Market Size and Forecast, By Delivery Mechanism

      • 12.4.13. India Neoantigen Market

        • 12.4.13.1. Market Size and Forecast, By Type
        • 12.4.13.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.4.13.3. Market Size and Forecast, By Product
        • 12.4.13.4. Market Size and Forecast, By Cell
        • 12.4.13.5. Market Size and Forecast, By Treatment
        • 12.4.13.6. Market Size and Forecast, By Technology
        • 12.4.13.7. Market Size and Forecast, By Route Of Administration
        • 12.4.13.8. Market Size and Forecast, By Delivery Mechanism

      • 12.4.14. South Korea Neoantigen Market

        • 12.4.14.1. Market Size and Forecast, By Type
        • 12.4.14.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.4.14.3. Market Size and Forecast, By Product
        • 12.4.14.4. Market Size and Forecast, By Cell
        • 12.4.14.5. Market Size and Forecast, By Treatment
        • 12.4.14.6. Market Size and Forecast, By Technology
        • 12.4.14.7. Market Size and Forecast, By Route Of Administration
        • 12.4.14.8. Market Size and Forecast, By Delivery Mechanism

      • 12.4.15. Australia Neoantigen Market

        • 12.4.15.1. Market Size and Forecast, By Type
        • 12.4.15.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.4.15.3. Market Size and Forecast, By Product
        • 12.4.15.4. Market Size and Forecast, By Cell
        • 12.4.15.5. Market Size and Forecast, By Treatment
        • 12.4.15.6. Market Size and Forecast, By Technology
        • 12.4.15.7. Market Size and Forecast, By Route Of Administration
        • 12.4.15.8. Market Size and Forecast, By Delivery Mechanism

      • 12.4.16. Thailand Neoantigen Market

        • 12.4.16.1. Market Size and Forecast, By Type
        • 12.4.16.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.4.16.3. Market Size and Forecast, By Product
        • 12.4.16.4. Market Size and Forecast, By Cell
        • 12.4.16.5. Market Size and Forecast, By Treatment
        • 12.4.16.6. Market Size and Forecast, By Technology
        • 12.4.16.7. Market Size and Forecast, By Route Of Administration
        • 12.4.16.8. Market Size and Forecast, By Delivery Mechanism

      • 12.4.17. Malaysia Neoantigen Market

        • 12.4.17.1. Market Size and Forecast, By Type
        • 12.4.17.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.4.17.3. Market Size and Forecast, By Product
        • 12.4.17.4. Market Size and Forecast, By Cell
        • 12.4.17.5. Market Size and Forecast, By Treatment
        • 12.4.17.6. Market Size and Forecast, By Technology
        • 12.4.17.7. Market Size and Forecast, By Route Of Administration
        • 12.4.17.8. Market Size and Forecast, By Delivery Mechanism

      • 12.4.18. Indonesia Neoantigen Market

        • 12.4.18.1. Market Size and Forecast, By Type
        • 12.4.18.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.4.18.3. Market Size and Forecast, By Product
        • 12.4.18.4. Market Size and Forecast, By Cell
        • 12.4.18.5. Market Size and Forecast, By Treatment
        • 12.4.18.6. Market Size and Forecast, By Technology
        • 12.4.18.7. Market Size and Forecast, By Route Of Administration
        • 12.4.18.8. Market Size and Forecast, By Delivery Mechanism

      • 12.4.19. Rest of Asia Pacific Neoantigen Market

        • 12.4.19.1. Market Size and Forecast, By Type
        • 12.4.19.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.4.19.3. Market Size and Forecast, By Product
        • 12.4.19.4. Market Size and Forecast, By Cell
        • 12.4.19.5. Market Size and Forecast, By Treatment
        • 12.4.19.6. Market Size and Forecast, By Technology
        • 12.4.19.7. Market Size and Forecast, By Route Of Administration
        • 12.4.19.8. Market Size and Forecast, By Delivery Mechanism

    • 12.5. LAMEA

      • 12.5.1. Key Market Trends and Opportunities

      • 12.5.2. Market Size and Forecast, By Type

      • 12.5.3. Market Size and Forecast, By Therapeutic Specialty

      • 12.5.4. Market Size and Forecast, By Product

      • 12.5.5. Market Size and Forecast, By Cell

      • 12.5.6. Market Size and Forecast, By Treatment

      • 12.5.7. Market Size and Forecast, By Technology

      • 12.5.8. Market Size and Forecast, By Route Of Administration

      • 12.5.9. Market Size and Forecast, By Delivery Mechanism

      • 12.5.10. Market Size and Forecast, By Country

      • 12.5.11. Brazil Neoantigen Market

        • 12.5.11.1. Market Size and Forecast, By Type
        • 12.5.11.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.5.11.3. Market Size and Forecast, By Product
        • 12.5.11.4. Market Size and Forecast, By Cell
        • 12.5.11.5. Market Size and Forecast, By Treatment
        • 12.5.11.6. Market Size and Forecast, By Technology
        • 12.5.11.7. Market Size and Forecast, By Route Of Administration
        • 12.5.11.8. Market Size and Forecast, By Delivery Mechanism

      • 12.5.12. South Africa Neoantigen Market

        • 12.5.12.1. Market Size and Forecast, By Type
        • 12.5.12.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.5.12.3. Market Size and Forecast, By Product
        • 12.5.12.4. Market Size and Forecast, By Cell
        • 12.5.12.5. Market Size and Forecast, By Treatment
        • 12.5.12.6. Market Size and Forecast, By Technology
        • 12.5.12.7. Market Size and Forecast, By Route Of Administration
        • 12.5.12.8. Market Size and Forecast, By Delivery Mechanism

      • 12.5.13. Saudi Arabia Neoantigen Market

        • 12.5.13.1. Market Size and Forecast, By Type
        • 12.5.13.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.5.13.3. Market Size and Forecast, By Product
        • 12.5.13.4. Market Size and Forecast, By Cell
        • 12.5.13.5. Market Size and Forecast, By Treatment
        • 12.5.13.6. Market Size and Forecast, By Technology
        • 12.5.13.7. Market Size and Forecast, By Route Of Administration
        • 12.5.13.8. Market Size and Forecast, By Delivery Mechanism

      • 12.5.14. UAE Neoantigen Market

        • 12.5.14.1. Market Size and Forecast, By Type
        • 12.5.14.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.5.14.3. Market Size and Forecast, By Product
        • 12.5.14.4. Market Size and Forecast, By Cell
        • 12.5.14.5. Market Size and Forecast, By Treatment
        • 12.5.14.6. Market Size and Forecast, By Technology
        • 12.5.14.7. Market Size and Forecast, By Route Of Administration
        • 12.5.14.8. Market Size and Forecast, By Delivery Mechanism

      • 12.5.15. Argentina Neoantigen Market

        • 12.5.15.1. Market Size and Forecast, By Type
        • 12.5.15.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.5.15.3. Market Size and Forecast, By Product
        • 12.5.15.4. Market Size and Forecast, By Cell
        • 12.5.15.5. Market Size and Forecast, By Treatment
        • 12.5.15.6. Market Size and Forecast, By Technology
        • 12.5.15.7. Market Size and Forecast, By Route Of Administration
        • 12.5.15.8. Market Size and Forecast, By Delivery Mechanism

      • 12.5.16. Rest of LAMEA Neoantigen Market

        • 12.5.16.1. Market Size and Forecast, By Type
        • 12.5.16.2. Market Size and Forecast, By Therapeutic Specialty
        • 12.5.16.3. Market Size and Forecast, By Product
        • 12.5.16.4. Market Size and Forecast, By Cell
        • 12.5.16.5. Market Size and Forecast, By Treatment
        • 12.5.16.6. Market Size and Forecast, By Technology
        • 12.5.16.7. Market Size and Forecast, By Route Of Administration
        • 12.5.16.8. Market Size and Forecast, By Delivery Mechanism

  • CHAPTER 13: COMPETITIVE LANDSCAPE

    • 13.1. Introduction

    • 13.2. Top Winning Strategies

    • 13.3. Product Mapping Of Top 10 Player

    • 13.4. Competitive Dashboard

    • 13.5. Competitive Heatmap

    • 13.6. Top Player Positioning,2022

  • CHAPTER 14: COMPANY PROFILES

    • 14.1. Achilles Therapeutics Plc

      • 14.1.1. Company Overview

      • 14.1.2. Key Executives

      • 14.1.3. Company Snapshot

      • 14.1.4. Operating Business Segments

      • 14.1.5. Product Portfolio

      • 14.1.6. Business Performance

      • 14.1.7. Key Strategic Moves and Developments

    • 14.2. Advaxis, Inc.

      • 14.2.1. Company Overview

      • 14.2.2. Key Executives

      • 14.2.3. Company Snapshot

      • 14.2.4. Operating Business Segments

      • 14.2.5. Product Portfolio

      • 14.2.6. Business Performance

      • 14.2.7. Key Strategic Moves and Developments

    • 14.3. Frame Cancer Therapeutics

      • 14.3.1. Company Overview

      • 14.3.2. Key Executives

      • 14.3.3. Company Snapshot

      • 14.3.4. Operating Business Segments

      • 14.3.5. Product Portfolio

      • 14.3.6. Business Performance

      • 14.3.7. Key Strategic Moves and Developments

    • 14.4. Genocea

      • 14.4.1. Company Overview

      • 14.4.2. Key Executives

      • 14.4.3. Company Snapshot

      • 14.4.4. Operating Business Segments

      • 14.4.5. Product Portfolio

      • 14.4.6. Business Performance

      • 14.4.7. Key Strategic Moves and Developments

    • 14.5. Gradalis, Inc.

      • 14.5.1. Company Overview

      • 14.5.2. Key Executives

      • 14.5.3. Company Snapshot

      • 14.5.4. Operating Business Segments

      • 14.5.5. Product Portfolio

      • 14.5.6. Business Performance

      • 14.5.7. Key Strategic Moves and Developments

    • 14.6. Gritstone Oncology

      • 14.6.1. Company Overview

      • 14.6.2. Key Executives

      • 14.6.3. Company Snapshot

      • 14.6.4. Operating Business Segments

      • 14.6.5. Product Portfolio

      • 14.6.6. Business Performance

      • 14.6.7. Key Strategic Moves and Developments

    • 14.7. Immunicum AB

      • 14.7.1. Company Overview

      • 14.7.2. Key Executives

      • 14.7.3. Company Snapshot

      • 14.7.4. Operating Business Segments

      • 14.7.5. Product Portfolio

      • 14.7.6. Business Performance

      • 14.7.7. Key Strategic Moves and Developments

    • 14.8. Medigene AG

      • 14.8.1. Company Overview

      • 14.8.2. Key Executives

      • 14.8.3. Company Snapshot

      • 14.8.4. Operating Business Segments

      • 14.8.5. Product Portfolio

      • 14.8.6. Business Performance

      • 14.8.7. Key Strategic Moves and Developments

    • 14.9. Ziopharm Oncology, Inc.

      • 14.9.1. Company Overview

      • 14.9.2. Key Executives

      • 14.9.3. Company Snapshot

      • 14.9.4. Operating Business Segments

      • 14.9.5. Product Portfolio

      • 14.9.6. Business Performance

      • 14.9.7. Key Strategic Moves and Developments

    • 14.10. Moderna, Inc.

      • 14.10.1. Company Overview

      • 14.10.2. Key Executives

      • 14.10.3. Company Snapshot

      • 14.10.4. Operating Business Segments

      • 14.10.5. Product Portfolio

      • 14.10.6. Business Performance

      • 14.10.7. Key Strategic Moves and Developments

    • 14.11. Merck And Co. Inc

      • 14.11.1. Company Overview

      • 14.11.2. Key Executives

      • 14.11.3. Company Snapshot

      • 14.11.4. Operating Business Segments

      • 14.11.5. Product Portfolio

      • 14.11.6. Business Performance

      • 14.11.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NEOANTIGEN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL NEOANTIGEN MARKET FOR NUCLEIC ACID, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL NEOANTIGEN MARKET FOR DENDRITIC ACID, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL NEOANTIGEN MARKET FOR TUMOR CELL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL NEOANTIGEN MARKET FOR SYNTHETIC LONG PEPTIDE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL NEOANTIGEN MARKET, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL NEOANTIGEN MARKET FOR GASTROINTESTINAL CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL NEOANTIGEN MARKET FOR LUNG CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL NEOANTIGEN MARKET FOR SOLID TUMOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL NEOANTIGEN MARKET FOR URINARY SYSTEMS CANCERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL NEOANTIGEN MARKET FOR MELANOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL NEOANTIGEN MARKET FOR HEAD AND NECK CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL NEOANTIGEN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL NEOANTIGEN MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL NEOANTIGEN MARKET FOR PERSONALIZED NEO-ANTIGEN VACCINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL NEOANTIGEN MARKET FOR OFF-THE SHELL NEO-ANTIGEN VACCINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL NEOANTIGEN MARKET, BY CELL, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL NEOANTIGEN MARKET FOR AUTOLOGOUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL NEOANTIGEN MARKET FOR ALLOGENEIC, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL NEOANTIGEN MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 21. GLOBAL NEOANTIGEN MARKET FOR COMBINATION THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. GLOBAL NEOANTIGEN MARKET FOR MONO THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. GLOBAL NEOANTIGEN MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 24. GLOBAL NEOANTIGEN MARKET FOR WHOLE GENOME SEQUENCING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 25. GLOBAL NEOANTIGEN MARKET FOR RNA SEQUENCING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 26. GLOBAL NEOANTIGEN MARKET FOR HLA TYPING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 27. GLOBAL NEOANTIGEN MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 28. GLOBAL NEOANTIGEN MARKET FOR INTRAVENOUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 29. GLOBAL NEOANTIGEN MARKET FOR INTRAMUSCULAR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 30. GLOBAL NEOANTIGEN MARKET FOR TRANSDERMAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 31. GLOBAL NEOANTIGEN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 32. GLOBAL NEOANTIGEN MARKET, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 33. GLOBAL NEOANTIGEN MARKET FOR GENE GUN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 34. GLOBAL NEOANTIGEN MARKET FOR ELECTROPORATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 35. GLOBAL NEOANTIGEN MARKET FOR LIPOSOMES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 36. GLOBAL NEOANTIGEN MARKET FOR VIROSOMES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 37. GLOBAL NEOANTIGEN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 38. GLOBAL NEOANTIGEN MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 39. NORTH AMERICA NEOANTIGEN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 40. NORTH AMERICA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. NORTH AMERICA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 42. NORTH AMERICA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 43. NORTH AMERICA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 44. NORTH AMERICA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 45. NORTH AMERICA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 46. NORTH AMERICA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 47. NORTH AMERICA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 48. U.S. NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. U.S. NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 50. U.S. NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 51. U.S. NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 52. U.S. NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 53. U.S. NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 54. U.S. NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 55. U.S. NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 56. CANADA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CANADA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 58. CANADA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 59. CANADA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 60. CANADA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 61. CANADA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 62. CANADA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 63. CANADA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 64. MEXICO NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 65. MEXICO NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 66. MEXICO NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 67. MEXICO NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 68. MEXICO NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 69. MEXICO NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 70. MEXICO NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 71. MEXICO NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 72. EUROPE NEOANTIGEN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 73. EUROPE NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 74. EUROPE NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 75. EUROPE NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 76. EUROPE NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 77. EUROPE NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 78. EUROPE NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 79. EUROPE NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 80. EUROPE NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 81. FRANCE NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 82. FRANCE NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 83. FRANCE NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 84. FRANCE NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 85. FRANCE NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 86. FRANCE NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 87. FRANCE NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 88. FRANCE NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 89. GERMANY NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 90. GERMANY NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 91. GERMANY NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 92. GERMANY NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 93. GERMANY NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 94. GERMANY NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 95. GERMANY NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 96. GERMANY NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 97. ITALY NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 98. ITALY NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 99. ITALY NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 100. ITALY NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 101. ITALY NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 102. ITALY NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 103. ITALY NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 104. ITALY NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 105. SPAIN NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 106. SPAIN NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 107. SPAIN NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 108. SPAIN NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 109. SPAIN NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 110. SPAIN NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 111. SPAIN NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 112. SPAIN NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 113. UK NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 114. UK NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 115. UK NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 116. UK NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 117. UK NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 118. UK NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 119. UK NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 120. UK NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 121. RUSSIA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 122. RUSSIA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 123. RUSSIA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 124. RUSSIA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 125. RUSSIA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 126. RUSSIA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 127. RUSSIA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 128. RUSSIA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 129. REST OF EUROPE NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 130. REST OF EUROPE NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 131. REST OF EUROPE NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 132. REST OF EUROPE NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 133. REST OF EUROPE NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 134. REST OF EUROPE NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 135. REST OF EUROPE NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 136. REST OF EUROPE NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 137. ASIA-PACIFIC NEOANTIGEN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 138. ASIA-PACIFIC NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 139. ASIA-PACIFIC NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 140. ASIA-PACIFIC NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 141. ASIA-PACIFIC NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 142. ASIA-PACIFIC NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 143. ASIA-PACIFIC NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 144. ASIA-PACIFIC NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 145. ASIA-PACIFIC NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 146. CHINA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 147. CHINA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 148. CHINA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 149. CHINA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 150. CHINA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 151. CHINA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 152. CHINA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 153. CHINA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 154. JAPAN NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 155. JAPAN NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 156. JAPAN NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 157. JAPAN NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 158. JAPAN NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 159. JAPAN NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 160. JAPAN NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 161. JAPAN NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 162. INDIA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 163. INDIA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 164. INDIA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 165. INDIA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 166. INDIA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 167. INDIA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 168. INDIA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 169. INDIA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 170. SOUTH KOREA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 171. SOUTH KOREA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 172. SOUTH KOREA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 173. SOUTH KOREA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 174. SOUTH KOREA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 175. SOUTH KOREA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 176. SOUTH KOREA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 177. SOUTH KOREA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 178. AUSTRALIA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 179. AUSTRALIA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 180. AUSTRALIA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 181. AUSTRALIA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 182. AUSTRALIA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 183. AUSTRALIA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 184. AUSTRALIA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 185. AUSTRALIA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 186. THAILAND NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 187. THAILAND NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 188. THAILAND NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 189. THAILAND NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 190. THAILAND NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 191. THAILAND NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 192. THAILAND NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 193. THAILAND NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 194. MALAYSIA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 195. MALAYSIA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 196. MALAYSIA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 197. MALAYSIA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 198. MALAYSIA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 199. MALAYSIA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 200. MALAYSIA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 201. MALAYSIA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 202. INDONESIA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 203. INDONESIA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 204. INDONESIA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 205. INDONESIA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 206. INDONESIA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 207. INDONESIA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 208. INDONESIA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 209. INDONESIA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 210. REST OF ASIA PACIFIC NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 211. REST OF ASIA PACIFIC NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 212. REST OF ASIA PACIFIC NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 213. REST OF ASIA PACIFIC NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 214. REST OF ASIA PACIFIC NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 215. REST OF ASIA PACIFIC NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 216. REST OF ASIA PACIFIC NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 217. REST OF ASIA PACIFIC NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 218. LAMEA NEOANTIGEN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 219. LAMEA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 220. LAMEA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 221. LAMEA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 222. LAMEA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 223. LAMEA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 224. LAMEA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 225. LAMEA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 226. LAMEA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 227. BRAZIL NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 228. BRAZIL NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 229. BRAZIL NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 230. BRAZIL NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 231. BRAZIL NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 232. BRAZIL NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 233. BRAZIL NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 234. BRAZIL NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 235. SOUTH AFRICA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 236. SOUTH AFRICA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 237. SOUTH AFRICA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 238. SOUTH AFRICA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 239. SOUTH AFRICA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 240. SOUTH AFRICA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 241. SOUTH AFRICA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 242. SOUTH AFRICA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 243. SAUDI ARABIA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 244. SAUDI ARABIA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 245. SAUDI ARABIA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 246. SAUDI ARABIA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 247. SAUDI ARABIA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 248. SAUDI ARABIA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 249. SAUDI ARABIA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 250. SAUDI ARABIA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 251. UAE NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 252. UAE NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 253. UAE NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 254. UAE NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 255. UAE NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 256. UAE NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 257. UAE NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 258. UAE NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 259. ARGENTINA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 260. ARGENTINA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 261. ARGENTINA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 262. ARGENTINA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 263. ARGENTINA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 264. ARGENTINA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 265. ARGENTINA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 266. ARGENTINA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 267. REST OF LAMEA NEOANTIGEN, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 268. REST OF LAMEA NEOANTIGEN, BY THERAPEUTIC SPECIALTY, 2022-2032 ($MILLION)
  • TABLE 269. REST OF LAMEA NEOANTIGEN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 270. REST OF LAMEA NEOANTIGEN, BY CELL, 2022-2032 ($MILLION)
  • TABLE 271. REST OF LAMEA NEOANTIGEN, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 272. REST OF LAMEA NEOANTIGEN, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 273. REST OF LAMEA NEOANTIGEN, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 274. REST OF LAMEA NEOANTIGEN, BY DELIVERY MECHANISM, 2022-2032 ($MILLION)
  • TABLE 275. ACHILLES THERAPEUTICS PLC: KEY EXECUTIVES
  • TABLE 276. ACHILLES THERAPEUTICS PLC: COMPANY SNAPSHOT
  • TABLE 277. ACHILLES THERAPEUTICS PLC: OPERATING SEGMENTS
  • TABLE 278. ACHILLES THERAPEUTICS PLC: PRODUCT PORTFOLIO
  • TABLE 279. ACHILLES THERAPEUTICS PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 280. ADVAXIS, INC.: KEY EXECUTIVES
  • TABLE 281. ADVAXIS, INC.: COMPANY SNAPSHOT
  • TABLE 282. ADVAXIS, INC.: OPERATING SEGMENTS
  • TABLE 283. ADVAXIS, INC.: PRODUCT PORTFOLIO
  • TABLE 284. ADVAXIS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 285. FRAME CANCER THERAPEUTICS: KEY EXECUTIVES
  • TABLE 286. FRAME CANCER THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 287. FRAME CANCER THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 288. FRAME CANCER THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 289. FRAME CANCER THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 290. GENOCEA: KEY EXECUTIVES
  • TABLE 291. GENOCEA: COMPANY SNAPSHOT
  • TABLE 292. GENOCEA: OPERATING SEGMENTS
  • TABLE 293. GENOCEA: PRODUCT PORTFOLIO
  • TABLE 294. GENOCEA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 295. GRADALIS, INC.: KEY EXECUTIVES
  • TABLE 296. GRADALIS, INC.: COMPANY SNAPSHOT
  • TABLE 297. GRADALIS, INC.: OPERATING SEGMENTS
  • TABLE 298. GRADALIS, INC.: PRODUCT PORTFOLIO
  • TABLE 299. GRADALIS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 300. GRITSTONE ONCOLOGY: KEY EXECUTIVES
  • TABLE 301. GRITSTONE ONCOLOGY: COMPANY SNAPSHOT
  • TABLE 302. GRITSTONE ONCOLOGY: OPERATING SEGMENTS
  • TABLE 303. GRITSTONE ONCOLOGY: PRODUCT PORTFOLIO
  • TABLE 304. GRITSTONE ONCOLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 305. IMMUNICUM AB: KEY EXECUTIVES
  • TABLE 306. IMMUNICUM AB: COMPANY SNAPSHOT
  • TABLE 307. IMMUNICUM AB: OPERATING SEGMENTS
  • TABLE 308. IMMUNICUM AB: PRODUCT PORTFOLIO
  • TABLE 309. IMMUNICUM AB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 310. MEDIGENE AG: KEY EXECUTIVES
  • TABLE 311. MEDIGENE AG: COMPANY SNAPSHOT
  • TABLE 312. MEDIGENE AG: OPERATING SEGMENTS
  • TABLE 313. MEDIGENE AG: PRODUCT PORTFOLIO
  • TABLE 314. MEDIGENE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 315. ZIOPHARM ONCOLOGY, INC.: KEY EXECUTIVES
  • TABLE 316. ZIOPHARM ONCOLOGY, INC.: COMPANY SNAPSHOT
  • TABLE 317. ZIOPHARM ONCOLOGY, INC.: OPERATING SEGMENTS
  • TABLE 318. ZIOPHARM ONCOLOGY, INC.: PRODUCT PORTFOLIO
  • TABLE 319. ZIOPHARM ONCOLOGY, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 320. MODERNA, INC.: KEY EXECUTIVES
  • TABLE 321. MODERNA, INC.: COMPANY SNAPSHOT
  • TABLE 322. MODERNA, INC.: OPERATING SEGMENTS
  • TABLE 323. MODERNA, INC.: PRODUCT PORTFOLIO
  • TABLE 324. MODERNA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 325. MERCK AND CO. INC: KEY EXECUTIVES
  • TABLE 326. MERCK AND CO. INC: COMPANY SNAPSHOT
  • TABLE 327. MERCK AND CO. INC: OPERATING SEGMENTS
  • TABLE 328. MERCK AND CO. INC: PRODUCT PORTFOLIO
  • TABLE 329. MERCK AND CO. INC: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NEOANTIGEN MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NEOANTIGEN MARKET
  • FIGURE 3. SEGMENTATION NEOANTIGEN MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NEOANTIGEN MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNEOANTIGEN MARKET
  • FIGURE 11. NEOANTIGEN MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. NEOANTIGEN MARKET FOR NUCLEIC ACID, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. NEOANTIGEN MARKET FOR DENDRITIC ACID, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. NEOANTIGEN MARKET FOR TUMOR CELL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. NEOANTIGEN MARKET FOR SYNTHETIC LONG PEPTIDE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. NEOANTIGEN MARKET SEGMENTATION, BY BY THERAPEUTIC SPECIALTY
  • FIGURE 17. NEOANTIGEN MARKET FOR GASTROINTESTINAL CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. NEOANTIGEN MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. NEOANTIGEN MARKET FOR SOLID TUMOR, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. NEOANTIGEN MARKET FOR URINARY SYSTEMS CANCERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. NEOANTIGEN MARKET FOR MELANOMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. NEOANTIGEN MARKET FOR HEAD AND NECK CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. NEOANTIGEN MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. NEOANTIGEN MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 25. NEOANTIGEN MARKET FOR PERSONALIZED NEO-ANTIGEN VACCINE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. NEOANTIGEN MARKET FOR OFF-THE SHELL NEO-ANTIGEN VACCINE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. NEOANTIGEN MARKET SEGMENTATION, BY BY CELL
  • FIGURE 28. NEOANTIGEN MARKET FOR AUTOLOGOUS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. NEOANTIGEN MARKET FOR ALLOGENEIC, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. NEOANTIGEN MARKET SEGMENTATION, BY BY TREATMENT
  • FIGURE 31. NEOANTIGEN MARKET FOR COMBINATION THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 32. NEOANTIGEN MARKET FOR MONO THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 33. NEOANTIGEN MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 34. NEOANTIGEN MARKET FOR WHOLE GENOME SEQUENCING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 35. NEOANTIGEN MARKET FOR RNA SEQUENCING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 36. NEOANTIGEN MARKET FOR HLA TYPING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 37. NEOANTIGEN MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 38. NEOANTIGEN MARKET FOR INTRAVENOUS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 39. NEOANTIGEN MARKET FOR INTRAMUSCULAR, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 40. NEOANTIGEN MARKET FOR TRANSDERMAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 41. NEOANTIGEN MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 42. NEOANTIGEN MARKET SEGMENTATION, BY BY DELIVERY MECHANISM
  • FIGURE 43. NEOANTIGEN MARKET FOR GENE GUN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 44. NEOANTIGEN MARKET FOR ELECTROPORATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 45. NEOANTIGEN MARKET FOR LIPOSOMES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 46. NEOANTIGEN MARKET FOR VIROSOMES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 47. NEOANTIGEN MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 48. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 51. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 52. COMPETITIVE DASHBOARD
  • FIGURE 53. COMPETITIVE HEATMAP: NEOANTIGEN MARKET
  • FIGURE 54. Top player positioning, 2022
  • FIGURE 55. ACHILLES THERAPEUTICS PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. ACHILLES THERAPEUTICS PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. ACHILLES THERAPEUTICS PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. ADVAXIS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. ADVAXIS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. ADVAXIS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 61. FRAME CANCER THERAPEUTICS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. FRAME CANCER THERAPEUTICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 63. FRAME CANCER THERAPEUTICS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 64. GENOCEA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. GENOCEA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 66. GENOCEA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 67. GRADALIS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. GRADALIS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 69. GRADALIS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 70. GRITSTONE ONCOLOGY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 71. GRITSTONE ONCOLOGY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 72. GRITSTONE ONCOLOGY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 73. IMMUNICUM AB: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 74. IMMUNICUM AB: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 75. IMMUNICUM AB: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 76. MEDIGENE AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 77. MEDIGENE AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 78. MEDIGENE AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 79. ZIOPHARM ONCOLOGY, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 80. ZIOPHARM ONCOLOGY, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 81. ZIOPHARM ONCOLOGY, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 82. MODERNA, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 83. MODERNA, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 84. MODERNA, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 85. MERCK AND CO. INC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 86. MERCK AND CO. INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 87. MERCK AND CO. INC: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Neoantigen Market

Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers